Pioglitazone, a peroxisome proliferator activated receptor-γ agonist, is associated with improvements in vascular stiffness and various cardiometabolic parameters in patients with systemic lupus erythematosus, show study findings.
A 35-year follow-up study has identified a 27.1% lifetime recurrence rate of axial spondyloarthritis among first-degree relatives of patients with human leukocyte antigen HLA-B27-positive ankylosing spondylitis.
Measures of right ventricular function could provide “crucial information” to predict which patients with systemic sclerosis are at high risk for poor outcomes, researchers report in Arthritis Research & Therapy.
Sequential treatment with rituximab followed by mepolizumab may be a promising strategy to treat the systemic and respiratory manifestations of eosinophilic granulomatosis with polyangiitis, suggest findings from an observational study.
Risk stratification in the primary care setting may not lead to significant improvements in pain or function for people with musculoskeletal disorders, but may have benefits for clinical decision-making, the UK-based STarT MSK trial shows.
Tumor necrosis factor inhibitor use by pregnant women with well-controlled rheumatoid arthritis is associated with a reduced risk for having a child that is born small for gestational age, study findings indicate.
Findings from a systematic review and meta-analysis indicate that viscosupplementation does not significantly improve pain and physical function in people with knee osteoarthritis, but increases the risk for serious adverse events.
Recurrent venous thromboembolism is more common in people with granulomatosis with polyangiitis than among individuals in the general population who had an unprovoked first event, US researchers report in Rheumatology Advances in Practice.
Follow-up results from the BE ACTIVE and BE AGILE phase 2b trials show that the efficacy and safety profiles of bimekizumab are maintained for up to 3 years in patients with psoriatic arthritis or ankylosing spondylitis.
Development of ustekinumab as a potential therapeutic option for systemic lupus erythematosus has been terminated following an interim analysis of the phase 3 LOTUS trial, which demonstrated no benefit of the IL-12/23 inhibitor in this patient population.